<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172639</url>
  </required_header>
  <id_info>
    <org_study_id>CareRA</org_study_id>
    <secondary_id>2008-007225-39</secondary_id>
    <nct_id>NCT01172639</nct_id>
  </id_info>
  <brief_title>Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.</brief_title>
  <official_title>A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>P. Verschueren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Combinatietherapie Bij Reumatoide Artritis (CoBRA) trial was a milestone in the
      development of the present treatment paradigm for Rheumatoid Arthritis (RA). This study
      introduced the principle of fast remission induction by means of a combination of standard
      Disease Modifying AntiRheumatic Drugs (DMARDs) and a step down bridge therapy with high dose
      glucocorticoids in early Rheumatoid Arthritis.

      The purpose of the present study is to compare different combinations of traditional DMARDs
      and glucocorticoids, based on the original CoBRA protocol, for treatment of early Rheumatoid
      Arthritis.

      Besides the efficacy and effectiveness of these strategies, patient centered outcomes and
      potential implementation problems of such treatment strategies are evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission</measure>
    <time_frame>week 16</time_frame>
    <description>proportion in remission defined by a Disease Activity Score based on the 28 joint count (DAS28)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>remission</measure>
    <time_frame>week 52</time_frame>
    <description>proportion in remission defined by a DAS28 (co-primary end point)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>remission</measure>
    <time_frame>week 104</time_frame>
    <description>proportion in remission defined by a DAS28 (co-primary end point)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>week 16</time_frame>
    <description>efficacy as defined by:
Disease activity: proportion responders according to the criteria of the European League Against Rheumatism (EULAR)
Functionality: proportion Clinically Meaningfull (CM) Health Assessment Questionnaire (HAQ) responders and proportion HAQ = 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effectiveness</measure>
    <time_frame>week 16</time_frame>
    <description>Proportion of treatment failures due to efficacy/effectiveness problems
Proportion with unplanned treatment changes
Proportion lost from follow up
Total cumulative steroid dose / mean steroid dose per day
Proportion started on biologics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>up to week 104</time_frame>
    <description>number and type of (serious) adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>week 28</time_frame>
    <description>efficacy as defined by:
Disease activity: proportion EULAR responders
Functionality: proportion CM HAQ responders and proportion HAQ = 0
radiographical score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>week 52</time_frame>
    <description>efficacy as defined by:
Disease activity: proportion EULAR responders
Functionality: proportion CM HAQ responders and proportion HAQ = 0
radiographical score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>week 104</time_frame>
    <description>efficacy as defined by:
Disease activity: proportion EULAR responders
Functionality: proportion CM HAQ responders and proportion HAQ = 0
radiographical score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effectiveness</measure>
    <time_frame>week 52</time_frame>
    <description>Proportion of treatment failures due to efficacy/effectiveness problems
Proportion with unplanned treatment changes
Proportion lost from follow up
Total cumulative steroid dose / mean steroid dose per day
Proportion started on biologics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effectiveness</measure>
    <time_frame>week 104</time_frame>
    <description>Proportion of treatment failures due to efficacy/effectiveness problems
Proportion with unplanned treatment changes
Proportion lost from follow up
Total cumulative steroid dose / mean steroid dose per day
Proportion started on biologics</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CoBRA classic high risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoBRA slim high risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MTX
Step down steroid half dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoBRA avant-garde high risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MTX
Leflunomide
Step down steroid half dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoBRA slim low risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MTX
Step down steroid half dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tight Step Up low risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MTX
No additional oral steroids allowed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>randomisation</intervention_name>
    <description>Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
    <arm_group_label>CoBRA classic high risk group</arm_group_label>
    <arm_group_label>CoBRA slim high risk group</arm_group_label>
    <arm_group_label>CoBRA avant-garde high risk group</arm_group_label>
    <arm_group_label>CoBRA slim low risk group</arm_group_label>
    <arm_group_label>Tight Step Up low risk group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA as defined by the 1987 revised American College of Rheumatology (ACR)
             criteria

          -  Early RA (less than 1 year)

          -  Use a reliable method of contraception for women of childbearing potential

          -  Able and willing to give written informed consent and participate in the study

        Exclusion Criteria:

          -  Previous treatment with DMARDs

          -  Previous treatment with oral corticosteroids at a dosage of more than 10 milligrams
             (mg) prednisone within 4 weeks before baseline

          -  Previous treatment with oral corticosteroids at a dosage equal to or less than 10 mg
             prednisone within 2 weeks before baseline

          -  Previous treatment with oral corticosteroids for more than 4 weeks

          -  Previous treatment with Intra Articular corticosteroids within 4 weeks before baseline

          -  Previous treatment with an investigational drug for the treatment or prevention of RA

          -  Contraindications for corticosteroids

          -  Contraindications for DMARDs

          -  Psoriatic Arthritis

          -  Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions,
             chronic or latent infectious diseases or immune deficiency which in the opinion of the
             investigator places the patient at an unacceptable risk for participation in the study

          -  Pregnancy, breastfeeding or no use of a reliable method of contraception

          -  Alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Verschueren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASZ</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Lucas</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reuma praktijk</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumacentrum</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent, dept. of Rheumatology</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reuma instituut Hasselt</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumapraktijk</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Yperman Ziekenhuis</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HHart Ziekenhuis</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCH</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St maarten</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri Serruys ziekenhuis</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol. 2009 May-Jun;38(3):166-72. doi: 10.1080/03009740802484846.</citation>
    <PMID>19169906</PMID>
  </reference>
  <reference>
    <citation>Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford). 2008 Jan;47(1):59-64. Epub 2007 Nov 26.</citation>
    <PMID>18039681</PMID>
  </reference>
  <reference>
    <citation>Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007 Dec;56(12):3919-27.</citation>
    <PMID>18050189</PMID>
  </reference>
  <reference>
    <citation>Esselens G, Westhovens R, Verschueren P. Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Musculoskeletal Care. 2009 Mar;7(1):1-16. doi: 10.1002/msc.136.</citation>
    <PMID>18618520</PMID>
  </reference>
  <reference>
    <citation>Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309-18. Erratum in: Lancet 1998 Jan 17;351(9097):220.</citation>
    <PMID>9251634</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2010</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>P. Verschueren</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>CoBRA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

